A 19-year-old male with a history significant for Crohn's disease presented for evaluation of persistent fever after drainage of a perirectal abscess. He had been on treatment with adalimumab for the last year. At admission, a chest radiograph showed a 2.1-cm mass-like opacity in the right hilar region (Figure 1). A contrast-enhanced chest CT scan was obtained (Siemens Sensation 64, Siemens Medical Solutions, Forcheim, Germany - 3 mm slices with 2 mm overlap, 100 kV, and 180 mAs) which revealed a well-defined enhancing endobronchial lesion measuring 1.8 cm in the proximal aspect of the bronchus intermedius (Figure 2A,B). The endobronchial location was better demonstrated on the coronal reformatted images (Figure 2C). Subcentimeter nodular opacities in the posterior lower lobes and in the right upper lobe were also present. Right hilar lymphadenopathy was present as well.

These CT findings prompted bronchoscopic evaluation showed an endobronchial lesion (Figure 3). Endobronchial ultrasound (EBUS) and EBUS-guided transbronchial needle aspiration was performed (Figure 4). Pathology was consistent with a well differentiated atypical carcinoid tumor. Cultures of bronchoalveolar lavage obtained during bronchoscopy revealed Mycobacterium fortuitum infection, suggesting that the smaller nodules were infectious in nature. It is unclear if the smaller nodules observed in the lower lobes and right upper lobe were related to metastatic carcinoid or Mycobacterium fortuitum infection but further radiologic studies of the thorax showed reduced size and number of his micronodular disease.

An octreotide whole body scan was performed to...
determine if this represented a primary endobronchial process or a metastatic lesion from an abdominal source. There was intense tracer uptake associated with the bronchial tumor without additional foci of definite somatostatin avidity (Figure 5). Equivocal faint increased tracer uptake was found on the right lower quadrant of the abdomen interpreted as related to an area of prior bowel resection and re-anastomosis.

**Discussion**

The increased risk of development and progression of intestinal carcinomas in patients with Crohn’s disease (CD) has been well defined. Reported meta-analysis showed a 4 to 20-fold increased risk of developing colorectal carcinoma (1,2), and to a lesser extent lymphoma, leukemia, squamous cell carcinoma, and carcinoid tumors (3).

Published case series linking CD to abdominal carcinoid tumors indicates that they are usually found incidentally during surgery. A retrospective study done in 111 patients with CD that underwent bowel resection showed a 15 fold higher incidence of carcinoid tumors in Crohn patients compared to the controls, particularly in locations other than the site of surgery, suggesting that the development of carcinoid tumors could be secondary to distant pro-inflammatory mediators (1). Another case series found a
0.3% incidence of carcinoid tumors in appendectomies of patients with CD (4).

To our knowledge, after extensive literature research, there is a single previous case report of a pulmonary carcinoid tumor in a patient with anti-TNF therapy. That patient was found to have a 2-cm right upper lobe mass after pulmonary nodular opacities were incidentally discovered on an abdominal CT obtained for the assessment of perianal fistulas. Video-assisted thoracoscopic surgery (VATS) was performed revealing the presence of primary pulmonary carcinoid (5).

Carcinoid tumors have somatostatin receptors, therefore radionuclide-coupled octreotide is used for perioperative staging and follow up evaluation of metastatic disease and disease recurrence. Two small series reported high sensibility (up to 90%) and specificity (up to 86%) for the detection of primary and metastatic bronchial tumors in patients with histologically proved carcinoids (5,6). Indium 111-octreotide is the suggested method to rule out a primary abdominal origin of carcinoid tumors (7).

Patients with CD with CT findings of a well defined thoracic mass displayed characteristic prominent enhancement after the administration of intravenous contrast, should rise the suspicion of a carcinoid tumor (7,8). In these cases octreotide scanning technique is the recommended scan for the visualization of tumors with somatostatin receptor, in order to rule out a primary abdominal origin of the tumor (9).

Adalimumab has been proven to be an effective biological agent to induce and maintain clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressant (10,11). However, a recent meta-analysis on cancer risk with tumor necrosis factor alpha (TNF) inhibitors, found that almost 1% of 15,418 individuals randomized to anti-TNF therapy were diagnosed with cancer, compared to 0.6% of 7,486 individuals randomized to a comparator, representing increased relative risks associated with all anti-TNF for cancers specially for non-melanoma skin cancer (12).

Other studies have also associated anti-TNF agents to augmented incidence of non-Hodgkin’s lymphomas, endometrial cancer, and penile intraepithelial neoplasia (5,13,14). This may be related to possible permissive growth of neoplasia when suppressing TNFα (12,15).

This is the second case report of a primary carcinoid tumor of the lung in a patient with Crohn disease; however it is the first case to show a bronchial location, which is indeed the most frequent location for carcinoid tumors. The possibility of distant carcinoid related to proinflammatory mediators has been proposed in the etiology of these tumors, and modest evidence relates them to the use of immunomodulators. Although both cases were diagnosed in patients treated with Adalumimab, the role of immunomodulators in the development of carcinoid tumors remains unclear.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References
